Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement (MTA) with an undisclosed pharmaceutical company, referred to as PharmaCO, originally signed on August 30, 2024. The agreement has been extended through December 31, 2026, to accommodate the time needed for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1 drugs. This extension allows both parties to continue their collaboration under the MTA, maintain the temporary exclusive license, and explore further strategic planning discussions involving PharmaCO's human clinical and business development teams.
The significance of this extension lies in the potential for Lexaria's patented DehydraTECH technology to improve oral delivery of GLP-1 drugs, a class of therapeutics widely used for diabetes and weight management. Over the past year, Lexaria has advanced its GLP-1 program with three key studies: Human Study #7, Animal Study #1, and Animal Study #2. All studies are fully funded with existing corporate resources, and results are expected in the third and fourth quarters of 2026. These studies aim to provide comprehensive evidence to support further collaboration and potential licensing of Lexaria's technology.
The MTA extension indicates sustained interest from PharmaCO in evaluating DehydraTECH, which has repeatedly demonstrated the ability to increase bio-absorption, reduce side effects, and enhance drug delivery across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 granted patents and additional patents pending worldwide. For more information, visit Lexaria's website.
Forward-looking statements in this press release involve risks and uncertainties, including the timing and outcomes of research studies, regulatory approvals, and market conditions. Lexaria disclaims any obligation to update these statements except as required by law.
